GRACEcast: Recent Episodes
Howard (Jack) West, MD
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit CancerGRACE.org for more info.
Jennifer Brown, MD, discusses the choice in chemoimmunotherapy, FCR (fludarabine, cyclophosphamide and rituximab) vs BR. FCR has been the standard therapy for previously untreated fit patients with CLL under about the age of 70. While BR (bendamustine and rituximab), is a relatively newer therapy, which had been studied in a couple of phase two trials - smaller single arm trials and look to be promising.
Lung Cancer Video Library ASCO 2016 - Rachel Sanborn - Adjuvant Chemotherapy for Elderly and Frail Patients
Lung Cancer Video Library - Rachel Sanborn - Adjuvant Chemotherapy for Early Stage NSCLC Patients, part 1
GRACE is happy to present the 6th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss Immuno-oncology developments - combinations and use as first-Line therapy.
GRACE is happy to present the 5th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the J-Alex trial and whether Alecensa should replace Xalkori as First-Line ALK Therapy.
GRACE is happy to present the 8th video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer. Featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016. Drs. Weiss, Bauml and Seiwert discuss the promising early data for the oral inhibitor Buparlisib.
7th video in our series ASCO 2016 Head and Neck Roundtable, featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD. Dr. Weiss moderates the discussion regarding ASCO 2016 HN RT-Using Immunotherapy as First-Line Treatment and in Combinations.
6th video in our series ASCO 2016 Head and Neck Roundtable, featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD. Dr. Weiss moderates the discussion regarding keynote 55: Pembrolizumab for heavily pre-treated patients.
GRACE is happy to present the 3rd video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer. Featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016. Drs. Weiss, Bauml and Seiwert discuss the using biomarkers in immunotherapy.
GRACE is happy to present the 4th video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer. Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016. Drs. Weiss, Baumi and Seiwert discuss the common side effects of PD-1 inhibitors.
GRACE is happy to present the 2nd video in our series, ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer. Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016. Drs. Weiss, Baumi and Seiwert discuss the subject of Checkmate 141 and its results.
GRACE is happy to present the 4th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the subject of local consolidation therapies for oligomatastases.
GRACE is happy to present the 1st video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer. Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016. Drs. Weiss, Baumi and Seiwert discuss the subject of the immune system and PD-1 inhibitors.
GRACE is happy to present our ASCO 2016 Lung Cancer Roundtable series, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing topics presented at ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the subject of urine or blood testing instead of lung biopsy, showing promise for finding EGFR mutations.
GRACE is happy to present our ASCO 2016 Lung Cancer Roundtable series, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing topics presented at ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the subject of online patient groups and if they can help speed the development of new targeted therapies. A subject quite important to online groups such as our own GRACE.
1st Video in the GRACE ASCO 2016 Lung Cancer Roundtable series, featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD. Dr. West moderates this roundtable discussion highlighting studies presented at ASCO 2016. For this video, Rova-T is presented as showing promise in Small Cell Lung Cancer.
CLL, Chronic Lymphocytic Leukemia, What is the significance of IGHV mutations and how they are assessed. Presented by Jennifer Brown, M.D., Ph.D., Director of the CLL Center and the Dana-Farber Cancer Institute.
Dr. Jack West, Swedish Cancer Institute, discusses current trials
seeking to determine the efficacy of combining immunotherapy agents
in lung cancer.
Dr. Jack West, Swedish Cancer Institute, raises the question of
whether to use immune checkpoint inhibitors as first-line treatment
of lung cancer, alone or in combination with
chemotherapy.
Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in diagnosis and staging.
Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.
Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.
Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.
Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.
Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.
Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.
Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority of NSCLC patients.
Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.
Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.
Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.
Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.
Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.
Dr. Ross Camidge, University of Colorado, describes ALK rearrangements and the characteristics of patients who most often have them.
Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.
Dr. Heather Wakelee, Stanford University Medical Center, discusses the purpose of adjuvant chemotherapy, and which patients benefit most from it.
Dr. Benjamin Levy, Mount Sinai Health Systems, compares zoledronic acid and denosumab, two agents used for treatment of bone metastases in lung cancer.
Dr. Benjamin Levy, Mount Sinai Health Systems, lists the goals of treating advanced NSCLC and the methods used to achieve those goals.
Dr. David Harpole, Duke University Medical Center, compares traditional open thoracotomy with video-assisted thorascopic surgery, highlighting the advantages of the newer approach.
Dr. David Harpole, Duke University Medical Center, defines the concept of mediastinal node sterilization and its use after neoadjuvant therapy.
Dr. David Harpole, Duke University Medical Center, describes the sleeve resection and how it can help selected patients with large tumors retain lung function.
Dr. David Harpole, Duke University Medical Center, describes the mediastinoscopy and its use in lung cancer staging.
Dr. David Harpole, Duke University Medical Center, describes how he assists patients with the surgical decision-making process.
Dr. Nasser Hanna, Indiana University Health, addresses the issue of prophylactic cranial irradiation (PCI) in locally advanced NSCLC.
Dr. Nasser Hanna, Indiana University Health, discusses the possible role of immunotherapy in locally advanced NSCLC.
Dr. Nasser Hanna, Indiana University Health, reviews efforts to utilize targeted therapies as consolidation after chemoradiation in locally advanced NSCLC.
Dr. Nasser Hanna, Indiana University Health, considers the use of induction or consolidation chemotherapy for unresectable stage III NSCLC.
Dr. Nasser Hanna, Indiana University Health, discusses the development of chemoradiation as a standard of care for unresectable stage III NSCLC.
Dr. Nasser Hanna, Indiana University Health, describes the factors which determine whether stage III NSCLC is resectable.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, details the trends in lung cancer demographics and changes in histology by race and gender.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the demographics and epidemiology of lung cancer.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the genetic risk (or lack thereof) for lung cancer.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, describes the types of situations in which local therapy is appropriate for treating limited acquired resistance.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, evaluates a variety of particular systemic treatment agents for possible use in elderly patients.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the use of single agent vs. doublet chemotherapy in elderly patients.
Dr. Gerard Silvestri, Medical University of South Carolina, describes the steps necessary to work up a lung cancer diagnosis, from initial scan to choice of treatment.
Dr. Gerard Silvestri, Medical University of South Carolina, discusses the use of PET scans in lung cancer workup.
Dr. Gerard Silvestri, Medical University of South Carolina, describes several procedures used to obtain biopsy tissue in order to diagnose lung cancer.
Dr. Gerard Silvestri, Medical University of South Carolina, describes some of the typical presenting symptoms of lung cancer.
Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.
Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.
Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.
Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of which must be treated.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines the V20 standard for lung radiation and outlines the advantages of limiting dose and field size in lung radiation therapy.
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, provides trial evidence showing that patients may not benefit from high dose chest radiation therapy vs. standard dose therapy.
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the history and current use of stereotactic radiation therapy for inoperable lung lesions.
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the use of stereotactic radiosurgery and stereotactic radiation therapy.
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC discusses the feasibility of molecular marker testing and targeted therapy in the adjuvant or post-operative setting.
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC describes the use of serum tumor markers in various types of cancer, and the lack of a useful serum tumor marker in lung cancer.
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC defines the concept of cancer histology and gives examples of several lung cancer subtypes.
Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center reviews early trial data of immunotherapy agents for treatment of small cell lung cancer (SCLC).
Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center discusses standard chemotherapy options for treatment of both sensitive and refractory small cell lung cancer (SCLC).
Dr. Craig L. Slingluff, University of Virginia, discusses novel approaches to immunotherapy, including adoptive T-cell therapy, personalized cancer vaccines and personalized selection of immune therapies.
Dr. Mario Sznol, Yale School of Medicine, provides a detailed description of the mechanism of action of immunotherapy agents and discusses early data on the use of combination therapies.
Dr. Julie Brahmer, Johns Hopkins University, discusses the use of biomarker testing and mutational burden to select patients for specific immunotherapies in lung cancer, renal cell carcinoma and melanoma.
Dr. Mario Sznol, Yale School of Medicine, provides an overview of melanoma and its treatment, and discusses current melanoma immunotherapies and other agents under investigation.
Dr. Julie Brahmer, Johns Hopkins University, discusses immunotherapies for NSCLC and SCLC, analyzes the relevant trial data and addresses the unique side effects of these therapies.
Dr. James Gulley, National Cancer Institute, discusses immunotherapies for genitourinary cancers, including recent trial results. He also addresses early data which may indicate that using immunotherapy sooner may benefit patients.
Dr. James Gulley, National Cancer Institute, gives an overview of the immune system and describes the mechanism of action of immunotherapy agents, as well as results from clinical trials.
Brendan Bietry of the Patient Advocate Foundation discusses the financial assistance programs available to lung cancer patients who receive targeted therapies.
Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.
Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.
There are sub-types within the sub-type of EGFR mutation positive lung cancer. In this presentation, Dr. Jack West discuss the different activating mutations within EGFR positive tumors and how they impact treatment.
Janet Daily-Freeman moderates a question & answer session with Drs. Leora Horn and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for ALK+ and ROS1 patients.
The brain is a common site of disease in patients with ALK+ lung cancer. In this video, Dr. Horn illustrates the line-up of ALK+ treatments and how they work breaking through the blood/brain barrier.
Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.
Dr. West moderates a question & answer session with Drs. Leora Horn and Taofeek OwonikokGreg Riely on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.
Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from new immunotherapy agents among patients with advanced NSCLC and an identified driver mutation.
Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biospies, including plasma sampling as a "liquid biopsy" option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.
Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.
Dr. Eddie Garon reviews the pattern of response to immunotherapy in lung cancer, along with the concept of "pseudoprogression".
Drs. Ben Solomon, Leora Horn, & Jack West review impressive data demonstrating a striking survival improvement from successful efforts at smoking cessation among smokers undergoing lung cancer CT screening.
Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.
Dr. Taofeek Owonikoko reviews why we often see brain metastases develop as a first or only site of progression in patients with NSCLC and a driver mutation.
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the evidence and consider whether there are clinically significant differences among the second generation ALK inhibitors that would lead to a reason to prefer one over another for a particular patient.
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.
As we learn more about immunotherapy for lung cancer, combinations with multiple immunotherapy agents are being explored. Medical oncologist Dr. Eddie Garon considers whether combinations are likely to emerge as the leading immunotherapy approach.
Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.
“Gratitude is one of the most medicinal emotions we can feel.” (Sara Avant Stover) Thank you for joining GRACE in our #LCAM15 activities.
Dr. Jack West reviews the Lung Cancer Master Protocol for second line treatment of patients with advanced squamous NSCLC, an "umbrella protocol" in which all patients undergo molecular testing and have treatment assigned by the results.
Dr. Ross Camidge talks about a clinical trial that will test to see if the drug tesevatinib will work to kill cancer that has progressed in the brains of EGFR-mutant lung cancer patients. The trial is scheduled to begin in late 2015 or early 2016.
On this Thanksgiving Day, we salute lung cancer patient Jason Karg and his wife Kristyl for reminding us of the important things in life. November is Lung Cancer Awareness Month. What are you grateful for?
Dr. Jack West reviews the concept of epigenetics, epigenetic priming, and whether oral azacytidine can improve outcomes in patients who receive immunotherapy for advanced lung cancer.
Dr. Ross Camidge discusses a clinical trial studying patients with advanced stage lung cancer to identify those who may respond to a drug called ponatinib. Both small cell and non small cell lung cancer patients may be eligible. http://bit.ly/UCponatinib
Dr. Seema Nagpal insists on one thing from her lung cancer patients: Proof that they are enjoying their lives. November is Lung Cancer Awareness Month. What are you grateful for?
Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.
Drs. Ben Solomon, Leora Horn, & Jack West assess the utility and limitations of "liquid biopsies", serum-based testing for molecular marker testing in lung cancer.
Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first line chemotherapy or targeted therapy vs. sequential treatment.
Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.
Drs. Leora Horn, Ben Solomon, & Jack West review the potential rationale and possible limitations of combining different immuntherapy strategies with one another.
Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.
Drs. Leora Horn, Ben Solomon, & Jack West consider the factors that might lead us to favor testing for PD-L1 at initial workup of a patient with advanced NSCLC or after progression.
Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and whether it should be integrated in clinical decision making around immunotherapies.
Dr. Ben Levy discusses two trials that are trying to determine if immunotherapy can help lung cancer patients with earlier stage disease. Click here for information about the PACIFIC trial. The lung cancer vaccine trial will begin in early 2016.
Dr. Nathan Pennell discusses ALCHEMIST, an NCI-sponsored clinical trial looking at whether targeted post-op (adjuvant) therapy for patients with a driver mutation such as EGFR mutation or ALK rearrangement improves survival. http://bit.ly/NCIALCHEMIST
ROS1 lung cancer patient Lisa Goldman credits research with keeping her alive. November is Lung Cancer Awareness Month. What are you grateful for?
Drs. Leora Horn, Ben Solomon, & Jack West review early promising data on the potential activity of immune checkpoint inhibitors in the treatment of malignant pleural mesothelioma.
GRACE Founder and President Dr. H. Jack West gives thanks to immunotherapies that offer new hope to his patients. November is Lung Cancer Awareness Month. What are you grateful for?
Even in the world of lung cancer, there are things to be grateful for. This November, join GRACE as we celebrate them with doctors, patients and caregivers.
Drs. Ben Solomon, Leora Horn, & Jack West review trial result and implications of ECOG 1505 trial that showed no benefit to addition of Avastin (bevacizumab) to adjuvant chemotherapy for early stage NSCLC.
Dr. Eddie Garon from UCLA Medical Center reviews the general mechanism of action of immune checkpoint inhibitors and how they can be an effective therapy in lung cancer.
Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.
Dr. Greg Reily from MSKCC provides an introduction to the epidermal growth factor receptor (EGFR), what an EGFR mutation means, and which patients are more likely to have them.
Memorial Sloan-Kettering Cancer Center medical oncologist Dr. Greg Riely explains how testing for specific mutations in patients with advanced NSCLC can guide prognosis and treatment recommendations.
Dr. Vivek Mehta, radiation oncologist, reviews the basic principles and treatment approach for limited stage small cell lung cancer, which combines chest radiation with concurrent chemotherapy.
Why radiate a perfectly good brain? Dr. Vivek Mehta, radiation oncologist, discusses the possible role for prophylactic cranial irradiation (PCI) for extensive stage small cell lung cancer (SCLC) to decrease risk of brain metastases and improve survival.
Radiation to the brain is a component of our treatment of limited stage small cell lung cancer, even with no evidence of cancer there. Dr. Vivek Mehta, radiation oncologist, reviews why we would do such a thing.
Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.
The concept of maintenance therapy for advanced lung cancer has emerged over the past few years. Dr. Jack West, medical oncologist, reviews the concepts behind it and treatment options for patients.
Bronchioloalveolar carcinoma (BAC) is an unusual subtype of lung cancer; medical oncologist Dr. Jack West reviews the evidence on the best systemic therapy to treat advanced, multifocal BAC.
Radiation oncologist Dr. Chris Loiselle reviews the possibility of re-treating with radiation for lung cancer, typically using stereotactic technique, in a previously irradiated field.
Dr. Jack West, medical oncologist/lung cancer specialist, describes special management considerations for indolent lung cancers that may not require treatment or are at risk for "over-treatment."
Dr. Eric Vallieres, thoracic surgeon, introduces us to and provides a brief history for the special case in lung cancer of a "Pancoast Tumor", along with how its optimal treatment has evolved over several decades.
Dr. West reviews basic principles of treating locally advanced lung cancer, including the need to treat both local disease and possible distant disease, and the need to balance efficacy with toxicity.
Thoracic Surgeon Dr. Eric Vallieres reviews the principle of giving chemotherapy prior to lung cancer surgery in order to improve survival and potentially make it possible to do a smaller lung surgery.
Dr. Eric Vallieres, thoracic surgeon, discusses the potential to do smaller lung surgeries on patients with a lung cancer that poses a minimal risk of recurrence.
Current clinical trials are examining the possibility of giving kidney cancer (also called renal cell carcinoma, or RCC) patients immunotherapy as their first option of care upon diagnosis.
The immune checkpoint inhibitor Opdivo (nivolumab) has been shown to increase survival for patients with metastatic clear cell kidney cancer (also called renal cell carcinoma, or RCC).
Dr. Chris Loiselle, radiation oncologist, describes stereotactic body radiation therapy (SBRT) as a helpful and increasingly favored treatment option for sicker, "medically inoperable" patients with early stage lung cancer.
Should older patients with lung cancer undergo surgery? What issues affect the probability of an elderly patients safely undergoing lung cancer surgery. Dr. Eric Vallières, thoracic surgeon, provides an expert perspective.
Dr. Eric Vallières, thoracic surgeon, describes the phsycial challenges and risks for patients who undergo a pneumonectomy for lung cancer.
There are multiple different types of lung cancer surgery. Dr. Eric Vallières, thoracic surgeon, reviews the different forms of lung surgery, include wedge resection, segmentectomy, lobectomy, and pneumonectomy.
Dr. Eric Vallières, thoracic surgeon, reviews the structure and purpose of staging using the current tumor-node-metastasis (TNM) system for lung cancer.
Dr. Jed Gorden reviews the technique of pleurodesis to manage the complication of recurrent malignant pleural effusion (MPE).
A tunneled pleural catheter is an excellent way to manage the symptoms of a recurrent malignant pleural effusion. Dr. Jed Gorden describes how it is placed and how it works.
Dr. Jed Gorden describes the details of how a thoracentesis is performed in order to clarify the diagnosis and treat symptoms of a malignant pleural effusion (MPE).
Interventional pulmonologist Dr. Jed Gorden reviews malignant pleural effusions (MPEs) are a common complication of lung cancer and some other cancers.
What is the role for the neuroprotective agent memantine in patients receiving whole brain radiation therapy for brain metastases? Dr. Vivek Mehta reviews current practices to minimize risk of cognitive problems.
Radiation therapy can be very helpful in treating painful bone metastases or those at risk for causing a fracture due to compromise of bone strength. Dr. Vivek Mehta reviews the basics of this approach.
Liquid biopsies (also called serum testing) is a practice already approved in Europe for EGFR lung cancer patients. Drawing blood to test for acquired resistance is easier and quicker than needle biopsies. How long until it is standard practice in the US?
A study released at ASCO 2015 showed that the BRAF V600E mutation had a high response rate to combination therapy Tafinlar (dabrafenib) plus Mekinist (trametinib), which led the doctors to agree that BRAF testing in lung cancer should become commonplace.
A French study presented at ASCO 2015 showed a survival benefit with Avastin (bevacizumab) added to standard chemo, unlike a prior US study. The doctors discuss the influence of this trial and future potential benefits from immunotherapy in mesothelioma.
Managing brain metastases is a big concern for lung cancer patients. The doctors discuss the drawbacks of whole brain radiotherapy and the fact that there are still unknowns regarding more targeted stereotactic radiosurgery.
A Japanese study of squamous cell carcinoma showed value in nedaplatin vs cisplatin/Taxotere (docetaxel). But with differences in how Asian versus Caucasian patients metabolize chemotherapy, can we presume this benefit would exist for everyone?
A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable target in lung cancer.
A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can identify only patients most likely to benefit from Cometriq.
Squamous cell carcinoma patients have limited options. Data presented at ASCO 2015 showed positive patient outcomes with Gilotrif (afatinib) vs Tarceva (erlotinib), but some feel that there is little value in a treatment with only modestly better results.
The current standard of care for SCLC shows limited results with high toxicities. Drs. Soria, Gandhi, and West discuss new ASCO 2015 data that show promise for a subset of patients with PD-L1 expression on Keytruda (pembrolizumab) or Opdivo (nivolumab).
As more immunotherapeutics become available to treat lung cancer, research must determine how to balance efficacy, toxicities, and cost. That means finding which patients who will benefit from which drugs while maintaining good quality of life.
Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action in the same clinical settings?
The immune checkpoint inhibitor Opdivo (nivolumab) shows better efficacy than Taxotere (docetaxel) for advanced non-squamous NSCLC, but this was seen only in patients with PD-L1 protein expression on their tumor. Should we be using this as a biomarker?
Research released at the 2015 American Society of Clinical Oncology (ASCO) annual meeting showed great promise for squamous cell lung cancer patients taking the immunotherapy drug Opdivo (nivolumab). But can we predict which patients will do well on it?
Radiation Oncologist Dr. Vivek Mehta reviews the concept of using whole brain radiation for multiple brain metastases, including how it is delivered and risks and benefits of this strategy.
Dr. Jack West reviews new techniques for evaluating mutations from blood, including detection of circulating tumor cells (CTCs) or mutations in circulating free DNA (cfDNA) that can replace at least some tissue biopsies.
Unfortunately, there is as much misinformation as good information about the unusual subtupe of lung cancer known as bronchioloalveolar carcinoma (BAC) or adenocarcinoma in situ. Dr. Jack West reviews the top 5 myths.
Bronchioloalveolar carcinoma (BAC), also known as adenocarcinoma in situ, is an unusual subtype of lung cancer with its own appearance under a microscope and on imaging. Dr. Jack West introduces some of the basics of the unique features of BAC.
Immunotherapy Forum Video #31: "You know the world is changing when you have to change the rules..." Following presentations on endpoints and biomarkers in cancer immunotherapy, the doctors take questions from the audience.
Immunotherapy Forum Video #30: Immunotherapy for cancer has rewritten the rules for what we consider a successful response to treatment. Some tumors grow before they regress. Dr. Jedd Wolchok discusses why a new measurement criteria was developed.
Immunotherapy Forum Video #29: In part 2 of 2, Dr. Jason Luke discusses treating cancer with immunotherapy and another drug, such chemotherapy or targeted therapies, as well as what we know about biomarkers that predict if an immunotherapeutic will work.
Immunotherapy Forum Video #28: Doctors are still weighing the pros and cons of giving a cancer patient immunotherapy before or after resection surgery. In part 1 of 2 videos, Dr. Jason Luke details those risks and benefits.
Immunotherapy Forum Video #27: Immunotherapies work well in some, but not in others. Who benefits, and why? Dr. Sumanta (Monty) Pal explains what doctors are learning.
Immunotherapy Forum Video #26: Drs. Jared Weiss and Matthew Hellmann answer questions from the audience following their presentations on immunotherapy for lung cancer. Moderated by Dr. Jack West.
Thoracic oncologist Dr. Ben Levy highlights what he believes was the biggest news for lung cancer patients in 2014 as well as his take on exciting clinical trials taking place in lung cancer in 2015.
Immunotherapy Forum Video #25: In Part 2 of 2 videos, Dr. Matthew Hellmann discusses currently enrolling clinical trials for lung cancer patients that study combination therapies (meaning an immunotherapy drug plus another drug is given).
Immunotherapy Forum Video #24: In Part 1 of 2 videos, Dr. Matthew Hellmann provides an overview of clinical trials currently available to early and late stage lung cancer patients that study single agent immunotherapies (i.e. only one treatment is given).
Immunotherapy Forum Video #23: Dr. Jared Weiss highlights what doctors know about immunotherapy treatments for lung cancer. His words: "The pace of progress that I expect over the next 3 to 5 years will shock even the most optimistic..."
Immunotherapy Forum Video #22: Drs. Lauren Harshman and Sumanta (Monty) Pal answer questions from the audience following their presentations on immunotherapy for kidney cancer. Moderated by Dr. Marianne Davies.
Immunotherapy Forum Video #21: Dr. Sumanta (Monty) Pal reviews the past, present, and future of immunotherapy for kidney cancer and expresses concern about early study results of newer treatments.
Immunotherapy Forum Video #20: Dr. Lauren Harshman talks about clinical trials studying the CTLA-4 pathway, as well as vaccines.
Immunotherapy Forum Video #19: Dr. Lauren Harshman discusses treating kidney cancer with immunotherapy. In this video, she focuses on clinical trials studying PD-1 and PDL-1 agents.
In Part 2 of 2 videos about squamous lung cancer, Dr. Chad Pecot explains the value of patients receiving molecular profiling of their tumor, the vital role of clinical trials, and the promise of immunotherapy for treating this type of lung cancer.
In Part 1 of 2 videos about squamous lung cancer, Dr. Chad Pecot explains what doctors look for and ask about when diagnosing lung cancer, and how you can be sure you received the correct diagnosis.
Immunotherapy Forum Video #18: Drs. Topalian and Wolchok sat for a moderated Q&A with Dr. Louise Perkins from the Melanoma Research Alliance following their presentations on immunotherapy for melanoma.
Immunotherapy Forum Video #17: In Part 2 of 2 videos on this topic, Dr. Jedd Wolchok discusses side effects related to immunotherapy, combination therapies, and information about new immunotherapies currently being studied for treating melanoma.
Immunotherapy Forum Video #16: In Part 1 of 2 videos on this topic, Dr. Jedd Wolchok provides a history of one of the first immunotherapy drugs, Yervoy (ipilumumab), and the evidence that led to its approval.
Immunotherapy Forum Video #15: In Part 2 of 2 videos on this topic, Dr. Suzanne Topalian discusses the immunotherapy drugs that are currently approved for the treatment of melanoma as well as future treatments on the horizon.
Immunotherapy Forum Video #14: In Part 1 of 2 videos on this topic, Dr. Suzanne Topalian provides a background on melanoma in the United States and how immunotherapy treatment for it has progessed over the past three decades.
Immunotherapy Forum Video #12: In Part 2 of 2 videos on this topic, Dr. Michael Atkins explains why immunotherapy appears to be more effective in such cancers as melanoma, lymphomas, and kidney, lung, bladder, and head and neck cancers.
Immunotherapy Forum Video #12: In Part 2 of 2 videos on this topic, Dr. Michael Atkins explains why immunotherapy appears to be more effective in such cancers as melanoma, lymphomas, and kidney, lung, bladder, and head and neck cancers.
Immunotherapy Forum Video #11: In Part 1 of 2 videos on this topic, Dr. Michael Atkins explains why immunotherapy appears to be more effective in such cancers as melanoma, lymphomas, and kidney, lung, bladder, and head and neck cancers.
Immunotherapy Forum Video #10: "For all of the scholarly individuals here to give you the science, I'm here to give you the proof," is how stage IV melanoma patient Rusty Cline kicks off the story of his remarkable response to immunotherapy.
Immunotherapy Forum Video #9: In Part 2 of 2 videos on this topic, oncology nurse Dr. Marianne Davies discusses the side effects that cancer patients who undergo immunotherapy treatment may experience and how to minimize them.
Immunotherapy Forum Video #8: In Part 1 of 2 videos on this topic, oncology nurse Dr. Marianne Davies discusses the side effects that cancer patients who undergo immunotherapy treatment may experience and how to minimize them.
Immunotherapy Forum Video #7: Drs. Pardoll, Hellman, and Luke sat for a moderated Q&A with Dr. Jack West.
Immunotherapy Forum Video #6: In Part 2 of 2 videos on this topic, Dr. Jason Luke from the University of Chicago talks about the types of immunotherapy currently in use for melanoma, kidney cancer, and lung cancer and how they are given to patients.
Immunotherapy Forum Video #5: In Part 1 of 2 videos on this topic, Dr. Jason Luke from the University of Chicago talks about the types of immunotherapy currently in use for melanoma, kidney cancer, and lung cancer and how they are given to patients.
Immunotherapy Forum Video #4: In Part 2 of 2 videos on this topic, Dr. Matthew Hellmann from the Memorial Sloan Kettering Cancer Center discusses the century-long history of attempting to treat cancer with immunotherapy.
Immunotherapy Forum Video #3: In Part 1 of 2 videos on this topic, Dr. Matthew Hellmann from the Memorial Sloan Kettering Cancer Center discusses the century-long history of attempting to treat cancer with immunotherapy.
Immunotherapy Forum Video #2: In Part 2 of 2 videos on this topic, Dr. Drew Pardoll from the Kimmel Cancer Center at Johns Hopkins explains what immunotherapy is and how it helps cancer patients live longer - many for five years or more.
Immunotherapy Forum Video #1: In Part 1 of 2 videos on this topic, Dr. Drew Pardoll from the Kimmel Cancer Center at Johns Hopkins explains what immunotherapy is and how it helps cancer patients live longer - many for five years or more.
Linnea Duff, a 10-year stage IV ALK+ lung cancer patient, gives thanks to GRACE this week and urges others to do the same.
November is Lung Cancer Awareness Month. To mark it this year, GRACE is celebrating the empowered lung cancer patient. In this video, Linnea Duff, a 10-year stage IV ALK+ lung cancer patient, shares her journey from stunned patient to empowered patient.
Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.
November is Lung Cancer Awareness Month. To mark it this year, GRACE is celebrating the empowered lung cancer patient. In this video, Dr. Jared Weiss, GRACE Vice President, and his patient Tomma Hargraves, discuss how they became a team.
Acquired Resistance Forum Video #14: Speakers from video #11 and video #12 at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.
Acquired Resistance Forum Video #13: Dr. Jack West of Swedish Cancer Institute discussed how the skyrocketing costs of cancer care are impacting whether or not some patients are able to get the right treatments.
Acquired Resistance Forum Video #12: Online advocate and ROS1 patient "Craig In PA" Uthe detailed how patients can educate themselves about their disease to understand and improve their personal situations. He also included his favorite online resources.
Acquired Resistance Forum Video #11: Bonnie J. Addario, founder of the Addario Lung Cancer Foundation described how the lung cancer community can work together to support each other and affect change for all patients.
Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.
Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.
Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.
Acquired Resistance Forum Video #7: Speakers from videos #5 and #6 at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.
Acquired Resistance Forum Video #6: Dr. Nate Pennell of the Cleveland Clinic discussed the other options available to patients with ALK, ROS1 and EGFR lung cancer, such as chemotherapy, Avastin, and immunotherapy.
Acquired Resistance Forum Video #5: Dr. Gideon Blumenthal of the US Food and Drug Administration (FDA) discussed the FDA process for approving targeted therapies.
Acquired Resistance Forum Video #4: The first three speakers at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.
Acquired Resistance Forum Video #3: Dr. Lecia Sequist of Massachusetts General Hospital detailed why doctors started doing repeat biopsies for patients receiving targeted therapies and how they help patients and doctors determine next steps in treatment.
Acquired Resistance Forum Video #2: Dr. Jared Weiss of the University of North Carolina addressed the Acquired Resistance in Lung Cancer Patient Forum with information on what patients' options are when their ALK, ROS1 or EGFR lung cancer progresses. September 2014
Acquired Resistance Forum Video #1: Dr. Gregory J. Riely of Memoral Sloan Kettering Cancer Center opened the Acquired Resistance in Lung Cancer Patient Forum with a basic introduction of how ALK, ROS1 and EGFR lung cancers become resistant to treatment. September 2014
Dr. Jack West, Dr. Julie Brahmer, and Dr. Ben Creelan discuss the excitement the medical community is feeling about immunotherapy for the treatment of lung cancer. February 2014
Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014
For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier. February 2014
For patients with wild type EGFR, meaning there is no EGFR mutation, drugs like Tarceva (erlotinib) can have a small benefit, but Dr. Joan Schiller wants research to do better. February 2014
Eighty percent of lung cancer patients have wild type EGFR, meaning there is no EGFR mutation. Dr. Joan Schiller of UT Southwestern Medical Center discusses a new drug in development that may help those patients. February 2014
The stigma of lung cancer can lead to shame, fear, and sub-optimal care. Dr. Joan Schiller wants us all to get past it, and she's leading the charge to make that happen. February 2014.
Does it make sense to do molecular testing on early stage lung cancer patients? Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute thinks it does in some settings. February 2014
Will the success seen for stage IV patients receiving targeted therapies translate into cure for stage III patients? Dr. Daniel Morgensztern of the Washington University School of Medicine talks about what research is ongoing to answer that question.
A current clinical trial (as of May 2014) asks if adding veliparib to chemo will increase progression free surival for late stage small cell lung cancer patients. For more information, visit clinicaltrials.gov and enter "ECOG 2511" in the search box.
Thanks to research, Dr. Daniel Morgensztern of the Washington University School of Medicine sees reason to be hopeful in the fight against lung cancer. February 2014
Research into small cell lung cancer may soon pay off in new treatments. Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute discusses new approaches that hold great promise. February 2014
HER2 inhibitors have been successfully used to combat breast cancer, but research has shown that a small percentage of lung cancer patients have a HER2 mutation as well. Dr. Leena Gandhi talks about the role that HER2 drugs may play to fight lung cancer.
Leptomeningeal carcinomatosis is cancer that has spread to the coating of the brain and spinal cord. In the past, prognosis has been bad. But now doctors are learning of effective treatments to deal with this issue.
The Northwest Medical Development Therapeutics Institute is breaking new ground by conducting clinical trials that will test treatments based on tumor mutations, rather than where the tumor began. Dr. Melissa Johnson describes the work of the center.
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes how he helps his EGFR lung cancer patients make decisions about next steps in treatment when their cancers grow.
Dr. Guru Sonpavde highlights the top research news in immunotherapy for kidney cancer from the ASCO 2014 Annual Meeting.
Biomarkers can give clues to many predictive and prognostic issues, like how a patient may respond to a drug or if a patient's cancer is likely to recur. Dr. Daniel Heng discusses what researchers are learning.
Dr. Lauren Harshman discusses what combinations of drugs are being studied in kidney cancer patients.
Cometriq (cabozantinib) is already approved for thyroid cancer and is showing promise for late stage kidney cancer.
Drs. Nasser Hanna and Melissa Johnson discuss developments in Immunotherapy since ASCO 2013.
Dr. Daniel Heng has advice to kidney cancer patients who want the best treatment for their disease. To find a clinical trial that is right for you, visit clinicaltrials.gov and enter "kidney cancer" in the search box.
Drs. Nasser Hanna and Melissa Johnson discuss new trial evidence for the use of adjuvant Eroltinib for early-stage lung cancer.
Predictive biomarkers can indicate if a patient will respond to a particular therapy. Dr. Lauren Harshman discusses if researchers know of any biomarkers for kidney cancer patients taking PD1 inhibitor drugs.
Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.
What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for to determine if a kidney cancer patient should be screened for a familial syndrome.
The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.
NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be most effective for them.
Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.
Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses.
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and how new drugs impact them to fight kidney cancer.
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.
Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperately needed to enroll in them.
"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).
Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.
Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.
Patients are responding very well to the next generation of immunotherapy drugs currently in clinical trials to treat kidney cancer.
Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.
Results from recent clinical trials looking into PD1 inhibitors of kidney cancer are giving patients and doctors reasons to be hopeful.
Fibroblast growth factor receptor (FGFR) mutations may play a role in the growth of squamous cell lung cancer. Dr. Jonathan Riess talks about what they are learning in this area.
EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.
"HSP 90 inhibitors are a really cool class of drugs..." states Dr. Melissa Johnson of the Robert H. Lurie Comprehensive Cancer Center as she describes what researchers are learning about these drugs still in early development. February 2014.
Among kidney cancer patients, the sub-type "non-clear cell" is the least common. As a result, not much research has been conducted on it.
An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.
Dr. Leena Gandhi of Dana-Farber Cancer Institute sees great potential in immune therapies for lung cancer. In this video, she expresses her hope and excitement for what the future may hold. February 2014.
Progression-free survival is something that doctors measure to determine how well a patient responds to a particular treatment. But does it translate to increased overall survival?
A genetic mutation and a leukemia drug may provide new hope for patients with squamous cell lung cancer patients.
Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab) to Tarceva helped EGFR positive lung cancer patients increase progression-free survival. June 2014.
Dr. Joel Neal of Stanford University Medical Center talks about FGFR - fibroblast growth factor receptor - and how it can impact non-small cell lung cancer growth.
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.
Dr. Jonathan Goldman discusses a drug currently being studied that may make lung cancer tumors more susceptible to treatment. February 2014.
How much detail is needed when determining how to treat lung cancer? Should patients be tested for all the mutations that may exist within their tumors? Dr. Jonathan Riess discusses this issue and how he makes decisions regarding his own patients.
Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also showing great promise. In this video, Dr. Leena Gandhi of Dana-Farber Cancer Institute talks about the research.
When it comes to EGFR and lung cancer, is a mutation good or bad? Dr. Joel Neal of Stanford University Medical Center explains why non-mutated genes are called "wild type." February 2014.
Immune therapy, or immunotherapy, is one of the most exciting areas of lung cancer research. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center explains how immune therapy works and how it might impact the future of lung cancer treatment.
What should lung cancer patients know about their disease? Dr. Jonathan Riess argues that patients should understand what type of lung cancer they have and which, if any, mutations their lung tumors may have. He explains why in this video.
If you were diagnosed with early stage lung cancer, should you receive molecular testing on your tumor in order to get targeted therapy? Dr. Joel Neal of Stanford University Medical Center discusses the reasons for and against it. February 2014.
Tarceva (erlotinib) has greatly helped EGFR positive lung cancer patients, but eventually it stops working. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center talks about the next generation EGFR inhibitors that may soon become available. February 2014.
Dr. Joel Neal of Stanford University Medical Center discusses the SELECT clinical trial which studied early stage non-small cell lung cancer patients and whether or not Tarceva (erlotinib) would prevent disease recurrence. February 2014.
Dr. Heather Wakelee of Stanford University Medical Center talks about how studies looking into Avastin (bevacizumab) for early stage lung cancer patients are progressing. February 2014.
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute discusses whether or not patients on targeted therapies, such as EGFR inhibitors, should stay on those therapies after their cancers begin to grow again. February 2014.
Dr. Charles Rudin of Memorial Sloan Kettering on the possibility of using vaccines to fight lung cancer. February 2014.
Dr. Heather Wakelee of Stanford University Medical Center talks about a drug still in development for EGFR lung cancer patients, CO-1686. February 2014.
Dr. Cathy Pietanza of Memorial Sloan Kettering explains how small cell lung cancer and non-small cell lung cancer are differentiated. February 2014.
Dr. Charles Rudin of Memorial Sloan Kettering talks about RAF and other genetic mutations that play a role in the growth of lung cancer. February 2014.
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute talks about exciting new developments which will allow oncologists to test patients' lung tumors without invasive biopsies. February 2014.
Dr. Charles Rudin of Memorial Sloan Kettering on how PARP inhibitors may benefit patients with small cell lung cancer. February 2014.
Dr. Cathy Pietanza of Memorial Sloan Kettering on the new avenues of research into the treatment of small cell lung cancer. February 2014.
Dr. Charles Rudin of Memorial Sloan Kettering discusses immune therapies that show promise in fighting lung cancer. February 2014.
Dr. Cathy Pietanza of Memorial Sloan Kettering on current and emerging treatments that are given to help keep small cell lung cancer from coming back after it has disappeared following initial therapy. February 2014.
Dr. Cathy Pietanza of Memorial Sloan Kettering talks about a drug currently in clinical trials that may successfully treat small cell lung cancer. February 2014.
Dr. Cathy Pietanza of Memorial Sloan Kettering discusses potential areas of success in the treatment of small cell lung cancer. February 2014.
Dr. Cathy Pietanza of Memorial Sloan Kettering offers suggestions for newly diagnosed small cell lung cancer patients. February 2014.
Dr. Cathy Pietanza of Memorial Sloan Kettering talks about the role of PARP inhibitors in the treatment of small cell lung cancer. February 2014.
Dr. Heather Wakelee of Stanford University Medical Center discusses whether or not cabozantinib - a drug already approved for thyroid cancer - can help patients with lung cancer. February 2014.
Dr. Edward Garon discusses what researchers are learning about MK-3475, an immune therapy treatment currently in clinical trial. February 2014.
Dr. Edward Garon warns that it is still too early to compare which immune therapies will be more effective in treating lung cancer.February 2014.
Dr. Cathy Pietanza of Memorial Sloan Kettering discusses whether PARP treatments can be taken alone or if they must be taken with other drugs. February 2014.
Dr. Jared Weiss, University of North Carolina, discusses chemotherapy options and practice in late stage oropharynx cancer.
Dr. Jared Weiss, University of North Carolina, discusses chemotherapy options and practice in late stage oropharynx cancer.
Why would an ALK lung cancer patient need a repeat biopsy? The doctors discuss the need for and frequency of repeat biopsies.
Several new treatments for ALK positive lung cancer patients are on the horizon. In this video, the doctors discuss them while patients in the audience share some of their experiences with side effects on various treatments.
New treatments for ALK rearrangements are on the horizon. In this video, the doctors discuss how they determine whether or not they change treatments for their patients once they begin to show progression while on Xalkori (crizotinib).
How often should ALK patients receive scans to determine if their disease has progressed in various parts of the body?
The doctors discuss how patients can navigate the tricky waters of stopping therapy while avoiding painful and sometimes life-threatening flare.
ALK positive lung cancer typically shows up in people do not appear to be at high risk for the disease, so is this something that a lung cancer patient can pass on to his or her children? The doctors discuss what research shows on this issue.
Who should be tested for ALK? How is ALK tested and how reliable are the results? In this video, the doctors discuss several issues surrounding the issue of testing for ALK, including what the medical guidelines suggest for testing lung cancer patients.
Xalkori (crizotinib) was one of the fastest approved drugs in cancer treatment history because of its high efficacy levels in ALK positive lung cancer patients. In this video, the doctors discuss what took place as it raced to approval.
The doctors discuss the history of ALK in lung cancer treatments and what the ALK rearragement means for patients.
Dr. Geoffrey Geiger, University of Pennsylvania, outlines the course of radiotherapy treatment and side effects for head and neck cancer.
Dr. Geoffrey Geiger, University of Pennsylvania, outlines the course of radiotherapy treatment and side effects for head and neck cancer.
Dr. Geoffrey Geiger, University of Pennsylvania, discusses the process of planning radiotherapy for head and neck cancer.
Dr. Geoffrey Geiger, University of Pennsylvania, discusses the process of planning radiotherapy for head and neck cancer.
Dr. Geoffrey Geiger, University of Pennsylvania, provides an introduction to head and neck cancer and the human papilloma virus.
Dr. Geoffrey Geiger, University of Pennsylvania, provides an introduction to head and neck cancer and the human papilloma virus.
Dr. David Spigel, Sarah Cannon Cancer Center, answers audience questions about squamous lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, answers audience questions about squamous lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, outlines treatment options for squamous lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, outlines treatment options for squamous lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, discusses the importance of genomic testing in squamous lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, discusses the importance of genomic testing in squamous lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, describes the diagnosis, presentation and workup of squamous lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, describes the diagnosis, presentation and workup of squamous lung cancer.
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews novel approaches, including nab-paclitaxel with gemcitabine, in advanced pancreatic cancer.
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews novel approaches, including nab-paclitaxel with gemcitabine, in advanced pancreatic cancer.
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, discusses the history of and recent developments in chemotherapy for metastatic pancreatic cancer.
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, discusses the history of and recent developments in chemotherapy for metastatic pancreatic cancer.
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the rationale and evidence for post-operative (adjuvant) therapy for resectable pancreatic cancer.
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the rationale and evidence for post-operative (adjuvant) therapy for resectable pancreatic cancer.
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the rationale and evidence for pre-operative (neoadjuvant) therapy for resectable pancreatic cancer.
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews the differentiation between resectable and unresectable pancreatic cancer.
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews the differentiation between resectable and unresectable pancreatic cancer.
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews the differentiation between resectable and unresectable pancreatic cancer.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews the landmark Biomarkers France study that tested a wide range of molecular markers in NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews the landmark Biomarkers France study that tested a wide range of molecular markers in NSCLC.
Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.
Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.
Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.
Dr. David Gerber, University of Texas-Southwestern, discusses results of two important trials of maintenance therapy in advanced NSCLC, including the PRONOUNCE trial and POINTBREAK trials.
Dr. David Gerber, University of Texas-Southwestern, discusses results of two important trials of maintenance therapy in advanced NSCLC, including the PRONOUNCE trial and POINTBREAK trials.
Dr. Rosalyn Juergens, McMaster University, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other LC subtypes.
Dr. Greg Riely, from Memorial Sloan-Kettering, describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular markers he prioritizes.
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the role of chemotherapy in pancreatic cancer, beginning with the molecular biology of pancreatic cancer.
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the role of chemotherapy in pancreatic cancer, beginning with the molecular biology of pancreatic cancer.
Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as introduction to key issues addressed in trials from ASCO 2013.
Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as introduction to key issues addressed in trials from ASCO 2013.
Dr. Bob Doebele from the University of Colorado, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.
Dr. Phil Bonomi, from Rush University, describes the generations of EGFR inhibitors beginning with Gefitinib (Iressa).
Dr. David Spigel, Sarah Cannon Cancer Center, describes which molecular markers he seeks for NSCLC patients.
Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews results from HPV-positive patients with head and neck cancer (HNSCC) from recent trials and describes emerging research in this population.
Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews results from HPV-positive patients with head and neck cancer (HNSCC) from recent trials and describes emerging research in this population.
Dr. Jared Weiss from the University of North Carolina, Chapel Hill introduces us to the human papilloma virus and its role as a cause and relevant prognostic factor for head and neck cancer (HNSCC).
GRACE, cancerGRACE, GRACEcast, Jared Weiss, Unveristy of North Carolina-Chapel Hill, UNC-Chapel Hill, induction therapy, neoadjuvant therapy, head and neck cancer, HNSCC, carbplatin, paclitaxel, cetuximab, Taxol, Erbitux, weekly
Dr. Jared Weiss from the University of North Carolina, reviews several options as induction therapy for head and neck cancer and focuses on the potential appeal and tolerability of the combination of weekly carboplatin and paclitaxel with cetuximab.
Dr. Jared Weiss from the University of North Carolina, reviews several options as induction therapy for head and neck cancer and focuses on the potential appeal and tolerability of the combination of weekly carboplatin and paclitaxel with cetuximab.
Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews the rationale for induction chemotherapy before surgery for head and neck cancer and highlights the early work that led to the emergence of the TPF regimen in this setting.
Dr. Jared Weiss from the University of North Carolina, Chapel Hill reviews the rationale for induction chemotherapy before surgery for head and neck cancer and highlights the early work that led to the emergence of the TPF regimen in this setting.
Dr. Ravi Salgia, from the University of Chicago, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
Dr. Sarah Goldberg gives her view on more widespread availability of new mutation tests, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other LC subtypes.
Dr. Bob Doebele from the University of Colorado, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.
Drs. Ross Camidge and Corey Langer describe which patients with advanced NSCLC they seek molecular marker testing on.
Dr. Greg Riely, from Memorial Sloan-Kettering, gives her view on more widespread availability of new mutation tests.
Drs. Mary Pinder, Nate Pennell, and Jack West discuss whether the finding of improving progression-free survival with maintenance sorafenib for SCLC should change the standard of care for treatment of extensive stage disease.
Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.
Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.
Drs. Nate Pennell, Mary Pinder, and Jack West discuss the START trial of L-BLP-25 (tecemotide) immunotherapy in locally advanced NSCLC.
Dr. Phil Bonomi, from Rush University, reviews his thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.
Dr. Rosalyn Juergens, McMaster University, reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.
Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
Drs. Nate Pennell, Mary Pinder, and Jack West discuss an encouraging study of dabrafenib, a BRAF inhibitor, for the limited number of NSCLC patients with a BRAF V600E mutation.
Dr. Mary Pinder of Moffitt Cancer Center reviews the CUSTOM trial, in which the study of molecular markers was expanded to patients with small cell lung cancer and thymic carcinomas.
Dr. David Spigel gives his view on more widespread availability of new mutation tests, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other lung cancer subtypes.
Dr. Heather Wakelee, from Stanford University, describes which molecular markers she seeks for NSCLC patients.
Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nindetanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.
Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.
Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.
Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.
Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, discusses the trend of patients consulting Dr.Google - finding information of varied quality on the internet.
Dr. Karen Kelly, of the University of California, Davis, gives her view on more widespread availability of new mutation tests.
Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PARAMOUNT trial of maintenance therapy with the ECOG 4599 regimen vs. carboplatin/Alimta (pemetrexed)/Avastin (bevacizumab) followed by Alimta/Avastin maint.
Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta.
Dr. Phil Bonomi, from Rush University, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
Drs. Mary Pinder, Nate Pennell, and Jack West review results from the PROSE trial presented at ASCO 2013, testing the predictive value of the Veristrat test of serum proteomics to assess the potential value of erlotinib (Tarceva) in advanced NSCLC.
Drs. Ross Camidge and Corey Langer describe their practice when patients with advanced NSCLC bring them the results of broad molecular marker testing.
Drs. Nate Pennell, Mary Pinder, and Jack West discuss trials presented at ASCO 2013 testing the potential value of molecular marker testing to select optimal chemo for advanced non-small cell lung cancer (NSCLC).
Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI discusses the evolution of our current best treatments for limited and extensive stage small cell lung cancer, as well as emerging potential therapies.
Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI discusses the evolution of our current best treatments for limited and extensive stage small cell lung cancer, as well as emerging potential therapies.
Drs. Nate Pennell, Mary Pinder, and Jack West discuss the Biomarkers France trial of testing on a national scale for clinically relevant biomarkers in advanced non-small cell lung cancer (NSCLC).
Dr. Greg Riely, from Memorial Sloan-Kettering, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, reviews his thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.
Dr. Rosalyn Juergens, McMaster University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.
Dr. Sarah Goldberg from Yale Cancer Center describes which patients with advanced NSCLC she seeks molecular marker testing on.
Dr. Ravi Salgia from the University of Chicago discusses the trend of patients consulting Dr.Google - finding information of varied quality on the internet.
Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI reviews the impact, causes, common symptoms, and approach to staging of small cell lung cancer.
Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI reviews the impact, causes, common symptoms, and approach to staging of small cell lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, gives his view on more widespread availability of new mutation tests.
Dr. Heather Wakelee, from Stanford University, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, describes the main types of kidney cancer and discusses the differences in their management
Dr. Greg Riely, from Memorial Sloan-Kettering, expresses his practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
Dr. Phil Bonomi, from Rush University, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.
Dr. Karen Kelly, of the University of California, Davis, reviews her thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews data supporting a method to define prognosis in early stage non-small cell lung cancer (NSCLC) based on molecular signatures and proposes a new staging system.
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews data supporting a method to define prognosis in early stage non-small cell lung cancer (NSCLC) based on molecular signatures and proposes a new staging system.
Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Dr. Rosalyn Juergens, McMaster University, discusses the question of widespread availability of new mutation tests under the Canadian health care system.
Dr. Sarah Goldberg from Yale Cancer Center describes which molecular markers she seeks for NSCLC patients.
Dr. Heather Wakelee, from Stanford University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).
Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, explains the range of options and his approach to second line treatment of kidney cancer.
Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, gives his view on whether a supercomputer such as Watson will be able to use complex algorithms to improve cancer care.
Dr. Ravi Salgia, University of Chicago, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, explains the potential utility of molecularly guided staging of patients with early stage non-small cell lung cancer (NSCLC).
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, explains the potential utility of molecularly guided staging of patients with early stage non-small cell lung cancer (NSCLC).
Dr. Karen Kelly, of the University of California, Davis expresses her practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
Dr. David Spigel, Sarah Cannon Cancer Center, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.
Dr. Rosalyn Juergens, McMaster University, reviews her thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.
Dr. Sarah Goldberg, from Yale Cancer Center, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified during first line chemotherapy. When should we switch treatments?
Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the evidence and his personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.
Dr. Phil Bonomi, from Rush University, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, explains the rationale and introduces the current standards and some potential variants for systemic therapy in patients with apparently localized pancreatic cancer.
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, explains the rationale and introduces the current standards and some potential variants for systemic therapy in patients with apparently localized pancreatic cancer.
Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, describes the role of surgery in the treatment of metastatic kidney cancer.
Drs. Ross Camidge and Corey Langer describe which patients with advanced NSCLC they seek molecular marker testing on, and the particular markers they prioritize.
Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, gives his view on more widespread availability of new mutation tests.
Dr. Ravi Salgia, University of Chicago, describes the CollabRx system, which matches patients with particular mutations to appropriate clinical trials.
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.
Dr. Karen Kelly, of the University of California, Davis, provides her thoughts on whether to continue an effective treatment beyond 4-6 cycles in an effort to exhaust the possible benefit from that treatment.
David Spigel, Sarah Cannon Cancer Center, reviews how he discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.
Dr. Sarah Goldberg, from Yale Cancer Center, offers her insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.
Dr. Lecia Sequist of Massachusetts General Hospital, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.
Dr. Rosalyn Juergens, McMaster University, addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential use in the adjuvant setting.
Dr. Greg Riely, from Memorial Sloan-Kettering, reviews his thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.
Drs. Ross Camidge and Corey Langer give their views on more widespread availability of new mutation tests.
Dr. Sumanta (Monty) Pal reviews the current role of chemotherapy in the treatment of kidney cancer.
Dr. Phil Bonomi, from Rush University, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
Dr. Karen Kelly of the University of California, Davis, provides her view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.
Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, TN expresses his practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
Dr. Sarah Goldberg from Yale Cancer Center describes the methods she uses to obtain tissue samples for molecular testing.
Dr. Lecia Sequist of Massachusetts General Hospital offers her insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, covers what surgery for pancreatic cancer entails, what the recovery process is like, and the importance of surgeon experience in outcomes.
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, covers what surgery for pancreatic cancer entails, what the recovery process is like, and the importance of surgeon experience in outcomes.
Dr. Rosalyn Juergens, McMaster University, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, on what he sees as the most significant changes in cancer care in the last decade or two.
Dr. Ravi Salgia from University of Chicago describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular markers he prioritizes.
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, discusses the issue of patients or payers objecting to repeat biopsies.
Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.
Dr. Phil Bonomi, from Rush University, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.
Dr. Karen Kelly of the University of California, Davis, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.
Dr. David Spigel addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential application in the adjuvant setting.
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, discusses the factors that determine whether a person's pancreatic cancer is resectable and the importance of this factor in predicting clinical outcomes.
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, discusses the factors that determine whether a person's pancreatic cancer is resectable and the importance of this factor in predicting clinical outcomes.
Dr. Sarah Goldberg, Yale Cancer Center, reviews her thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.
Drs. Ross Camidge and Corey Langer provide their perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.
Dr. Lecia Sequist of Massachusetts General Hospital gives her view on more widespread availability of new mutation tests
Dr. Heather Wakelee from Stanford University offers her insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.
Dr. Ravi Salgia from University of Chicago discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
Dr. Karen Reckamp from City of Hope Cancer Center in Duarte, CA describes which patients with advanced NSCLC she seeks molecular marker testing on, and the particular markers she prioritizes.
Dr. Greg Riely offers his view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
Dr. Oxnard from Dana Farber Cancer Institute provides his insight on which patients with advanced non-small cell lung cancer he pursues molecular testing for, and which molecular markers are the highest priority.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 immunotherapy that has emerged as one of the most promising new developments in lung cancer from 2012.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 immunotherapy that has emerged as one of the most promising new developments in lung cancer from 2012.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, reviews the general concept of cancer staging, the basic workup and staging of pancreatic cancer, and the implications of this process on treatment recommendations.
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, reviews the general concept of cancer staging, the basic workup and staging of pancreatic cancer, and the implications of this process on treatment recommendations.
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, provides a general introduction to the form and function of the pancreas, along with a description of the magnitude of the impact of pancreatic cancer in the US.
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, provides a general introduction to the form and function of the pancreas, along with a description of the magnitude of the impact of pancreatic cancer in the US.
Dr. Sarah Goldberg addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential application in the adjuvant setting.
Dr. Lecia Sequist of Massachusetts General Hospital describes the new targets she envisions as relevant for effective treatments in lung cancer over the next several years.
Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.
Drs. Ross Camidge and Corey Langer offer their insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.
Dr. Sumanta (Monty) Pal reviews the questions on the role of surgery and what type of surgery to pursue for early stage kidney cancer.
Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, TN, discusses the evidence and his personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.
Dr. Alan Sandler from OHSU describes how acquired resistance to targeted therapies in lung cancer is similar to what is seen with chemo and comments on how he manages patients demonstrating gradual acquired resistance in advanced lung cancer.
Dr. Greg Riely, Memorial Sloan-Kettering, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.
Dr. Ravi Salgia from University of Chicago provides his general strategy for patients with advanced non-small cell lung cancer who are candidates for maintenance therapy after first line treatment.
Dr. William Pao explains the caveats of molecular testing in terms of differences in testing methods through different laboratories and the heterogeneity of molecular findings in different biopsies even within the same individual with lung cancer.
Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, explains the range of options and his approach to first line treatment of metastatic kidney cancer.
Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, discusses leading challenges he sees for effective delivery of the best cancer care over the next decade.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.
Dr. Geoffrey Oxnard conveys a central theme that the benefits of molecular oncology and optimal application of targeted therapies are dependent on a change in collecting tissue that works to obtain far more tissue than was historically required.
Dr. Heather Wakelee from Stanford University expresses her practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
Dr. Karen Reckamp, City of Hope Cancer Center, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
Dr. Rosalyn Juergens, McMaster University, explains her approach to management of acquired resistance to targeted therapies in patients with a "driver mutation" and respond well initially to treatment.
Dr. David Harpole of Duke University reviews advances in lung cancer surgery, covering techniques ranging from video-assisted thoracic surgery to robotic surgery to sub-lobar resections and other developments offering new promising alternatives.
Dr. David Harpole of Duke University reviews advances in lung cancer surgery, covering techniques ranging from video-assisted thoracic surgery to robotic surgery to sub-lobar resections and other developments offering new promising alternatives.
Dr. Alan Sandler, Oregon Health and Science University, considers the various options for maintenance therapy as well as a potential treatment break after first line treatment of advanced non-small cell lung cancer.
Dr. Sumanta (Monty) Pal of City of Hope Cancer Center discusses the current role of interleukin-2 (IL-2) in the context of many other treatment alternatives for metastatic renal cell carcinoma.
Dr. Karen Kelly of University of California, Davis, presents her current view on using molecular markers in early stage non-small cell lung cancer and explains the RADIANT study that she leads.
Dr. Bob Doebele from the University of Colorado reviews which molecular markers have the strongest evidence to support routine testing, and which patients with advanced non-small cell lung cancer he favors molecular testing for.
Dr. Sumanta (Monty) Pal, City of Hope Cancer Center, summarizes basic stages of bladder cancer, value of surgery, and survival benefit of neoadjuvant (pre-operative) chemotherapy for higher risk muscle-invasive bladder cancer.
Dr. Sarah Goldberg notes that while maintenance therapy after first line treatment of advanced NSCLC is always worthy of a discussion, many patients need and benefit from a break from treatment to recover before pursuing additional therapy.
Drs. Ross Camidge and Corey Langer offer their perspectives on the most encouraging emerging targets that could become valuable additions to our lung cancer treatment menu in the next several years.
Dr. David Spigel, Sarah Cannon Cancer Center, reviews which patients with lung cancer he feels should undergo molecular testing, as well as describing the potential value of immediate, reflex testing for molecular targets.
Dr. Larry Einhorn, Indiana University, expresses his concerns about the cost of developing cancer drugs and the challenge of paying for extremely expensive cancer treatments that are given in anticipation of modest clinical benefits.
Dr. Larry Einhorn, Indiana University, explains why some cancers such as testicular cancer can have such a high cure rate while most others are far more challenging to cure with our current systemic therapies, offering an optimistic view of the future.
Dr. Sumanta (Monty) Pal of City of Hope Cancer Center in Duarte, CA describes optimal management of kidney cancer that is confined to the kidney, including surgery and the role of any additional post-surgical treatment.
Dr. Lecia Sequist provides her thoughts on how molecular oncology can soon begin affecting treatment plans for a broader range of patients with lung cancer, including those with squamous NSCLC and other lung cancer histologies.
Dr. Greg Riely from Memorial Sloan-Kettering notes how he feels molecular marker results for patients with earlier stage lung cancer can potentially be valuable.
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes a wide range of options for best managing patients with advanced NSCLC who experience acquired resistance, the progression of cancer after a good initial response to a targeted therapy.
Dr. Karen Reckamp, City of Hope Cancer Center, reviews her thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.
Dr. William Pao describes how the developers of MyCancerGenome.org envision the website resource being used to help cancer patients, both now and in the future.
Dr. Rosalyn Juergens, McMaster Unievrsity, offers her perspective on the treatments emerging as showing the greatest promise as effective novel therapies for patients with lung cancer.
Dr. Ravi Salgia from University of Chicago explains his approach to management of acquired resistance to a targeted therapy for advanced NSCLC, both in the setting of a single area of progression and also when disease progression is more diffuse.
Dr. Alan Sandler, Oregon Health and Science University, describes how he sees very specialized molecular testing for lung cancer becoming increasingly available to oncologists seeing patients in the community setting.
Dr. Phil Bonomi provides his views on the value of maintenance therapy for advanced non-small cell lung cancer and the various alternatives among maintenance therapies compared with a break from treatment.
Dr. Bob Doebele from the University of Colorado offers his perspective on whether targeted therapies will be able to applied to broader populations of patients with advanced NSCLC than those primarily with minimal smoking histories and an adenocarcinoma.
Dr. Sumanta (Monty) Pal of City of Hope Cancer Center in Duarte, CA reviews a recommended approach to the workup of a kidney mass suspected to be a cancer.
Drs. Ross Camidge and Corey Langer discuss which patients with advanced NSCLC they would recommend should have a repeat biopsy if their initial tissue sample doesn't have sufficient tissue for molecular testing.
Dr. Sarah Goldberg reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.
Dr. Karen Kelly describes her thought process on which molecular markers are those clearly indicated for testing in patients with advanced NSCLC, as well as whether smoking status factors into her approach.
Dr. Heather Wakelee from Stanford University discusses the open question of whether patients with resectable or locally advanced NSCLC should have testing for molecular markers, as well as how we might use this information in clinical practice.
Dr. Greg Riely from Memorial Sloan-Kettering reviews strategies for managing acquired resistance to EGFR inhibitors and other targeted therapies in advanced non-small cell lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years.
Dr. Lecia Sequist describes the state of the art and her view of current best practices on molecular testing for advanced non-small cell lung cancer.
Dr. Geoffrey Oxnard describes the new finding of individuals with an inherited T790M mutation in the EGFR gene, the unclear significance of it, and a study being conducted to learn more about it.
Dr. William Pao describes the MyCancerGenome.org website and how data on a wide range of mutations is incorporated to build this database to help physicians and cancer patients identify the most promising targeted therapy options for them.